Impact of COVID-19 on autoimmune blistering diseases
- 2 February 2021
- journal article
- research article
- Published by Elsevier BV in Clinics in Dermatology
- Vol. 39 (3), 359-368
- https://doi.org/10.1016/j.clindermatol.2021.01.007
Abstract
No abstract availableFunding Information
- Sanofi
- Johnson and Johnson
- AbbVie
- Novartis
- UCB
- Amgen
- Eli Lilly and Company
- Roche
This publication has 58 references indexed in Scilit:
- Diagnosis and management of pemphigus: Recommendations of an international panel of expertsJournal of the American Academy of Dermatology, 2018
- Rituximab in pemphigusImmunotherapy, 2017
- SchleimhautpemphigoidDie Dermatologie, 2017
- First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trialThe Lancet, 2017
- Rituximab as first-line treatment of pemphigusThe Lancet, 2017
- Paradoxical worsening of pemphigus vulgaris following rituximab therapyBritish Journal of Dermatology, 2015
- Autoimmune blistering dermatoses as systemic diseasesClinics in Dermatology, 2014
- Les maladies bulleuses auto-immunesLa Revue de Médecine Interne, 2014
- Pemphigoid diseasesThe Lancet, 2013
- A Comparison of Oral and Topical Corticosteroids in Patients with Bullous PemphigoidThe New England Journal of Medicine, 2002